Ropes & Gray Represents TransMedics in Pricing of Public Offering of Common Stock

Ropes & Gray led a $70 million equity offering for TransMedics Group Inc., a medical technology organ transplant therapy company for patients with end-stage lung, heart and liver failure in the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares are being offered by TransMedics. In connection with the offering, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock. 

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by TransMedics, are expected to be $70 million.

The Transmedics team was led by capital markets partners Tara Fisher and Paul Kinsella (both of Boston) and included life sciences regulatory partner Albert Cacozza (Washington, D.C.).